Canaccord Genuity Reiterates a 'Buy' on Amicus Therapeutics (FOLD); Migalastat Ph3 Data Preview

July 30, 2012 8:48 AM EDT
Get Alerts FOLD Hot Sheet
Price: $9.60 +2.24%

Rating Summary:
    9 Buy, 7 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 26 | Down: 19 | New: 41
Trade Now! 
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Amicus Therapeutics (NASDAQ: FOLD) price target of $11.00.

Analyst, Ritu Baral, said, "Reiterate rating and price target on potential positive migalastat pivotal Fabry monoTx data Q3/12, chaperone/ERT comboTx for Fabry, Pompe. We think Q3 pivotal migalastat Fabry monoTx ’011 trial data will be a strong positive catalyst and that the trial has a high chance of success. We also expect positive full Ph2 AT2220/ERT Pompe combo data in Q3/12...We see excellent risk/reward: $5+ upside on success, but only $2-3 downside given floor valuation from comboTx program."

For an analyst ratings summary and ratings history on Amicus Therapeutics click here. For more ratings news on Amicus Therapeutics click here.

Shares of Amicus Therapeutics closed at $5.16 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, FDA

Related Entities

Canaccord Genuity